NasdaqGS - Delayed Quote • USD
PTC Therapeutics, Inc. (PTCT)
At close: 4:00 PM EDT
After hours: 4:04 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 12 | 13 | 14 |
| Avg. Estimate | -1.24 | -1.53 | -5.84 | -4.99 |
| Low Estimate | -1.93 | -2.66 | -8.45 | -9.16 |
| High Estimate | -0.56 | -1.06 | -2.66 | -1.95 |
| Year Ago EPS | -1.88 | -2.66 | -8.37 | -5.84 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 13 | 13 |
| Avg. Estimate | 170.21M | 148.67M | 605.22M | 618.36M |
| Low Estimate | 143.5M | 134.44M | 469.7M | 332.8M |
| High Estimate | 209.6M | 169.37M | 675.8M | 747.97M |
| Year Ago Sales | 220.38M | 213.81M | 937.82M | 605.22M |
| Sales Growth (year/est) | -22.80% | -30.50% | -35.50% | 2.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.3 | -1.24 | -1.17 | 0.5 |
| EPS Actual | -1.88 | -2.66 | -1.76 | -2.06 |
| Difference | -0.58 | -1.42 | -0.59 | -2.56 |
| Surprise % | -44.60% | -114.50% | -50.40% | -512.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.24 | -1.53 | -5.84 | -4.99 |
| 7 Days Ago | -1.25 | -1.54 | -5.87 | -4.96 |
| 30 Days Ago | -1.25 | -1.54 | -5.88 | -4.98 |
| 60 Days Ago | -1.43 | -1.71 | -6.07 | -4.81 |
| 90 Days Ago | -1.32 | -1.56 | -5.59 | -4.39 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 2 | 2 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | PTCT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 34.00% | -- | -- | 1.60% |
| Next Qtr. | 42.50% | -- | -- | 10.50% |
| Current Year | 30.20% | -- | -- | 5.20% |
| Next Year | 14.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -9.51% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/12/2024 |
| Maintains | Jefferies: Buy to Buy | 3/20/2024 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/8/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 3/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/1/2024 |
| Maintains | TD Cowen: Market Perform to Market Perform | 3/1/2024 |
Related Tickers
AGIO Agios Pharmaceuticals, Inc.
29.53
+0.34%
IMCR Immunocore Holdings plc
55.68
+1.72%
PRTA Prothena Corporation plc
21.16
+2.87%
ENTA Enanta Pharmaceuticals, Inc.
13.32
+0.68%
KURA Kura Oncology, Inc.
17.53
-0.85%
FOLD Amicus Therapeutics, Inc.
10.61
+2.71%
MORF Morphic Holding, Inc.
27.99
+1.74%
MGTX MeiraGTx Holdings plc
5.09
+1.60%
XENE Xenon Pharmaceuticals Inc.
39.88
-1.07%
MLTX MoonLake Immunotherapeutics
42.19
-0.14%